June 5th, 2014
An Adverse Event on Lisinopril: What Do You Say to Your Patient?
John Ryan, MD
In this scenario of an adverse event after taking a guideline-recommended dosage of lisinopril to lower BP, John Ryan asks, “What do you say to your patient?”
October 14th, 2013
The Benefits of Switching From Hydrochlorothiazide to Chlorthalidone: What’s Stopping Us?
Nicholas Bergfeld, BS, BA
Nicholas Bergfeld wonders what it will take to convince the medical community and the government that switching from hydrochlorothiazide to chlorthalidone is effective, economical, and life-saving for patients.
March 25th, 2013
Selections from Richard Lehman’s Literature Review: March 25th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the effect of aliskiren on postdischarge mortality and readmissions among those hospitalized for HF, PFO closure, and more.
January 25th, 2011
New Study Finds Hydrochlorothiazide Inferior To All Other BP Drugs
Larry Husten, PHD
At the dosages most often used, hydrochlorothiazide (HCTZ), the most widely used antihypertensive agent in the world, is “consistently inferior” to all other drugs, according to a new meta-analysis published in JACC. Franz Messerli and colleagues performed a systematic review of studies that compared HCTZ to other drugs using 24-hour ambulatory blood pressure monitoring and found […]
NEJM Journal Watch — Recent Cardiology Articles- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension
- Preventive PCI of Vulnerable Plaques Linked to Fewer Cardiac Events
- News from the ACC Scientific Session 2024